21:56:44 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-02-21 Bokslutskommuniké 2023
2023-11-10 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-09 Årsstämma 2023
2023-05-09 Kvartalsrapport 2023-Q1
2023-02-22 Bokslutskommuniké 2022
2022-12-13 Extra Bolagsstämma 2022
2022-11-16 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-05-13 Ordinarie utdelning GUARD 0.00 SEK
2022-05-12 Kvartalsrapport 2022-Q1
2022-05-12 Årsstämma 2022
2022-02-22 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-11-08 Extra Bolagsstämma 2021
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-14 Ordinarie utdelning GUARD 0.00 SEK
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-12 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-09-07 Extra Bolagsstämma 2020
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GUARD 0.00 SEK
2020-05-14 Årsstämma 2020
2020-05-14 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-27 Kvartalsrapport 2019-Q3
2019-10-23 Extra Bolagsstämma 2019
2019-08-27 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning GUARD 0.00 SEK
2019-05-29 Årsstämma 2019
2019-05-21 Kvartalsrapport 2019-Q1
2019-03-20 Bokslutskommuniké 2018
2019-01-24 Extra Bolagsstämma 2018
2018-11-21 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-06-01 Ordinarie utdelning GUARD 0.00 SEK
2018-05-31 Årsstämma 2018
2018-05-23 Kvartalsrapport 2018-Q1
2018-02-23 Bokslutskommuniké 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-24 Kvartalsrapport 2017-Q1
2017-05-19 Split GUARD 20:1
2017-04-28 Ordinarie utdelning GUARD 0.00 SEK
2017-04-27 Årsstämma 2017
2017-03-14 Extra Bolagsstämma 2017
2017-02-22 Bokslutskommuniké 2016
2016-11-18 Kvartalsrapport 2016-Q3
2016-08-19 Kvartalsrapport 2016-Q2
2016-05-03 Extra Bolagsstämma 2016
2016-04-28 Ordinarie utdelning GUARD 0.00 SEK
2016-04-27 Årsstämma 2016
2016-04-22 Kvartalsrapport 2016-Q1
2016-02-19 Bokslutskommuniké 2015
2015-11-02 Extra Bolagsstämma 2015
2015-10-30 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-05-29 Kvartalsrapport 2015-Q1
2015-05-18 Årsstämma 2015
2015-04-29 Ordinarie utdelning GUARD 0.00 SEK
2015-02-18 Bokslutskommuniké 2014
2014-11-19 Kvartalsrapport 2014-Q3
2014-10-13 Extra Bolagsstämma 2014
2014-08-20 Kvartalsrapport 2014-Q2
2014-04-14 Kvartalsrapport 2014-Q1
2014-04-03 Split GUARD 1:5
2014-03-26 Ordinarie utdelning GUARD 0.00 SEK
2014-03-25 Årsstämma 2014
2014-02-21 Bokslutskommuniké 2013
2013-11-12 Kvartalsrapport 2013-Q3
2013-08-15 Kvartalsrapport 2013-Q2
2013-05-22 Årsstämma 2013
2013-05-15 Kvartalsrapport 2013-Q1


ListaFirst North Stockholm
Guard Therapeutics bedriver utveckling av läkemedel inom området oxidativ stress. Bolaget fokuserar i första hand på forskning, utveckling och kommersialisering av läkemedel som avser att förhindra uppkomst och komplikationer av akuta njurskador. Läkemedlet har i prekliniska studier visat sig skydda exponerad vävnad och understödja regenerativa processer. Behandling av akuta njurskador i samband med hjärtkirurgi prioriteras i den kliniska utvecklingen.
2020-03-17 10:00:12


Guard Therapeutics today announced positive top line results from the final and highest dosage group as part of a clinical phase 1a study where single ascending doses (SAD) of the investigational drug ROSgardTM were administered to healthy subjects. ROSgard also demonstrated good pharmacokinetic properties and a favourable safety profile at this dosage level, which is higher than the one that is expected to be used in future patient studies. The next stage in the phase 1a programme is to study ROSgard in multiple ascending doses (MAD).


With what is called the SAD part of the clinical phase 1a study now successfully concluded, Guard Therapeutics will apply to commence dosage of ROSgard in multiple ascending doses (MAD) in healthy subjects, based on an existing conditional approval from the Swedish Medical Products Agency. The company is anticipating that it will be possible to conclude the remaining part of the phase 1a programme during summer 2020. In parallel with this, a separate phase 1 study is underway to document the investigational drug's pharmacokinetics in individuals with reduced kidney function who have not started dialysis treatment.


"The fact that we have now also been able to generate positive study results for ROSgard at a dosage level that is higher than that which is expected to be used in patient studies, further strengthens the investigational drug's profile in advance of its continued development", says Tobias Agervald, CEO of Guard Therapeutics.  


As previously announced, Guard Therapeutics expects to be able to conduct its first small-scale study as early as 2020 in patients who will be undergoing cardiac surgery.


For further information, please contact:

Tobias Agervald, CEO

Telephone: +46 (0)46-286 50 30

E-mail: tobias.agervald@guardtherapeutics.com

About Guard Therapeutics
Guard Therapeutics' investigational drug ROSgardTM has been documented in several pre-clinical studies to protect against cell and organ damage, including acute kidney damage, by counteracting oxidative stress and supporting regenerative processes. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm. Certified Adviser is Erik Penser Bank AB, tel. +46 (0)8-463 83 00, certifiedadviser@penser.se.


This constitutes information that Guard Therapeutics International AB (publ) is required to publish under the EU's Market Abuse Regulation. The information was submitted through the above contact for publication on 17 March 2020 at 10.00.

Document: https://eqs-cockpit.com/c/fncls.ssp?u=HGCOGDEFJW
Document title: Top-Line Results SAD Study 17 March 2020

Language: English
Company: Guard Therapeutics International AB
Scheelevägen 22
223 63 Lund
Phone: +46 46 286 50 30
E-mail: info@guardtherapeutics.com
Internet: www.guardtherapeutics.com
ISIN: SE0009973357
EQS News ID: 998447

Guard Therapeutics International AB / 108 Company Announcement

Dissemination of a Swedish Financial News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

End of Announcement EQS News Service

998447  17.03.2020